Investigating Kidney Injury in Primary Hyperparathyroidism Investigating Kidney Injury in Primary Hyperparathyroidism
Could certain biomarkers help detect subtle kidney damage in primary hyperparathyroidism?Clinical Endocrinology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 26, 2019 Category: Intensive Care Tags: Diabetes & Endocrinology Journal Article Source Type: news
Bone and Mineral Disorders | Medscape Bone and Mineral Disorders | Medscape
Review in-depth clinical information, latest medical news, and guidelines about bone and mineral disorders, including the most common etiologies, such as osteoporosis, renal osteodystrophy, Paget ' s disease, metabolic bone disease, and primary hyperparathyroidism. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news
PET/CT May Be Useful for Challenging Cases of Hyperparathyroidism PET/CT May Be Useful for Challenging Cases of Hyperparathyroidism
For patients with hyperparathyroidism, 18F-fluorocholine positron emission tomography - computed tomography (PET/CT) may be indicated in difficult cases and when first-line tests are negative or discordant, researchers suggest.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - June 11, 2019 Category: Radiology Tags: Diabetes & Endocrinology News Source Type: news
Potential new hyperparathyroidism treatment target
Manipulating a signaling pathway that involves protein semaphorin3d can reduce the size of enlarged parathyroids in mice and may be a new therapeutic target, according to data published in theJournal of Biological Chemistry.Medscape (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 10, 2019 Category: Endocrinology Source Type: news
Discovery Could Herald'Game Changer' for Hyperparathyroidism Discovery Could Herald'Game Changer' for Hyperparathyroidism
Discovery of a signaling protein in mice, which could ultimately lead to development of a drug,"is a potential game changer in the [future] treatment of hyperparathyroidism," says an expert.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 7, 2019 Category: Cancer & Oncology Tags: Diabetes & Endocrinology News Source Type: news
Signalling protein discovery may lead to drug-based therapies to treat hyperparathyroidism
(Duke-NUS Medical School) Singapore researchers discover protein that protects parathyroid glands from excessive growth, suggesting potential drug-based strategies to treat hyperparathyroidism and other relevant tumours. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 28, 2019 Category: International Medicine & Public Health Source Type: news
Parathyroid hormone levels do not determine risk of hyperparathyroidism complications
Parathyroid hormone levels of patients with primary hyperparathyroidism are not predictive of kidney stones or low bone density, according to research published inThe Journal of Clinical Endocrinology& Metabolism.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - April 5, 2019 Category: Endocrinology Source Type: news
Parathyroid Hormone Replacement Effective, Safe Long Term Parathyroid Hormone Replacement Effective, Safe Long Term
A 6-year open-label extension study of recombinant human parathyroid hormone shows efficacy, safety in treating chronic hyperparathyroidism.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 4, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Intraoperative Parathyroid Monitoring in Hyperparathyroidism Intraoperative Parathyroid Monitoring in Hyperparathyroidism
What are the benefits of parathyroid hormone monitoring during surgery for primary hyperparathyroidism?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 18, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
UCLA receives $15.2 million bequest from estate of entertainer Garry Shandling
A bequest of $15.2 million from the estate of entertainer Garry Shandling will advance research in several fields at theDavid Geffen School of Medicine at UCLA.Shandling, the comedian, actor, director, writer and producer who died in March 2016, earmarked the funds to benefit three units — the division of endocrinology, diabetes and hypertension; the division of infectious diseases; and the UCLA Agi Hirshberg Center for Pancreatic Diseases — as well as general medical research at the David Geffen S chool of Medicine, establishing a meaningful philanthropic legacy.His gift will establish and endow the Garry Shandling ...
Source: UCLA Newsroom: Health Sciences - February 5, 2019 Category: Universities & Medical Training Source Type: news
Active Vitamin D No Help for CV Events in Select CKD Patients (CME/CE)
(MedPage Today) -- Oral alfacalcidol flops in dialysis patients without secondary hyperparathyroidism (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 19, 2018 Category: Cardiology Source Type: news
Alfacalcidol Does Not Lower CV Risk in Dialysis, Trial Suggests Alfacalcidol Does Not Lower CV Risk in Dialysis, Trial Suggests
Alfacalcidol did not reduce the risk for cardiovascular events in patients without secondary hyperparathyroidism who were undergoing maintenance hemodialysis, the J-DAVID trial found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Nephrology News Source Type: news
Vitamin D Analogue No Help for CV Prevention in Hemodialysis Patients
(MedPage Today) -- Trial limited to patients without secondary hyperparathyroidism (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 13, 2018 Category: Urology & Nephrology Source Type: news
Amgen sues Durham generics company
California-based biopharmaceutical company Amgen (Nasdaq: AMGN) has filed a patent infringement lawsuit against growing generics company Accord Healthcare and parent company Intas Pharmaceuticals.
Amgen's lawsuit stems from Accord Healthcare's plans to manufacture and sell a generic version of Amgen's drug, Sensipar, for the management of a type of hyperparathyroidism that causes detrimentally-high levels of calcium in the body. Sensipar raked in about $1.7 billion in revenue for Amgen l ast year.
According… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 3, 2018 Category: American Health Authors: Jennifer Henderson Source Type: news
